Ashutosh Chilkoti
Overview:
Ashutosh Chilkoti is the Alan L. Kaganov Professor of Biomedical Engineering and Chair of the Department of Biomedical Engineering at Duke University.
My research in biomolecular engineering and biointerface science focuses on the development of new molecular tools and technologies that borrow from molecular biology, protein engineering, polymer chemistry and surface science that we then exploit for the development of applications that span the range from bioseparations, plasmonic biosensors, low-cost clinical diagnostics, and drug delivery.
Positions:
Alan L. Kaganov Distinguished Professor of Biomedical Engineering
Biomedical Engineering
Pratt School of Engineering
Professor of Biomedical Engineering
Biomedical Engineering
Pratt School of Engineering
Research Professor of Global Health
Duke Global Health Institute
Institutes and Provost's Academic Units
Professor in the Thomas Lord Department of Mechanical Engineering and Materials Science
Thomas Lord Department of Mechanical Engineering and Materials Science
Pratt School of Engineering
Professor in the Department of Chemistry
Chemistry
Trinity College of Arts & Sciences
Core Faculty in Innovation & Entrepreneurship
Duke Innovation & Entrepreneurship
Institutes and Provost's Academic Units
Member of the Duke Cancer Institute
Duke Cancer Institute
School of Medicine
Education:
Ph.D. 1991
University of Washington
Grants:
A novel sustained-release immunotoxin for treatment of glioblastoma multiforme
Administered By
Biomedical Engineering
Awarded By
National Institutes of Health
Role
Principal Investigator
Start Date
End Date
Plasmonically Enhanced Point-of-care Detection of Cardiac Biomarkers by a Smart Phone
Administered By
Electrical and Computer Engineering
Awarded By
National Institutes of Health
Role
Co Investigator
Start Date
End Date
Genetically Encoded Smart Biohybrid Materials
Administered By
Biomedical Engineering
Awarded By
National Institutes of Health
Role
Principal Investigator
Start Date
End Date
DMREF: Collaborative Research: High throughput Exploration of Sequence Space of Peptide Polymers that Exhibit Aqueous Demixing Phase Behavior
Administered By
Biomedical Engineering
Awarded By
National Science Foundation
Role
Principal Investigator
Start Date
End Date
In situ Enzymatic Synthesis of Aptamer Targeted Polynucleotide Drug Nanoparticles for Cancer Therapy
Administered By
Mechanical Engineering and Materials Science
Awarded By
National Institutes of Health
Role
Co Investigator
Start Date
End Date
Publications:
Surface Patterning
Surface patterning becomes an important tool in biomedical research and applications, as it enables systematic investigation of cell-biomaterial interaction as well as rapid, high-throughput tests for disease diagnosis and drug screening. Recent advances in three-dimensional patterning allow for recapitulation of cellular microenvironment, providing valuable insights into the interplay between biomolecules, cells and biomaterials and facilitating the generation of personalized tissues for regenerative medicine applications. In this chapter, we review a diverse set of surface patterning techniques and their applications for biomedical use. First, we present important figures-of-merit of surface patterning techniques that should be considered to identify an appropriate method for a particular application. Especially, we discuss common concerns and requirements that need to be addressed in patterning of biologically active substances. We then review various types of patterning techniques mainly on the working principle and interesting examples for biomedical applications.
Authors
Lee, JS; Hill, RT; Chilkoti, A; Murphy, WL
MLA Citation
Lee, J. S., et al. “Surface Patterning.” Biomaterials Science: An Introduction to Materials in Medicine, 2020, pp. 553–73. Scopus, doi:10.1016/B978-0-12-816137-1.00037-4.
URI
https://scholars.duke.edu/individual/pub1559275
Source
scopus
Published Date
Start Page
553
End Page
573
DOI
10.1016/B978-0-12-816137-1.00037-4
Brachytherapy via a depot of biopolymer-bound 131I synergizes with nanoparticle paclitaxel in therapy-resistant pancreatic tumours.
Locally advanced pancreatic tumours are highly resistant to conventional radiochemotherapy. Here we show that such resistance can be surmounted by an injectable depot of thermally responsive elastin-like polypeptide (ELP) conjugated with iodine-131 radionuclides (131I-ELP) when combined with systemically delivered nanoparticle albumin-bound paclitaxel. This combination therapy induced complete tumour regressions in diverse subcutaneous and orthotopic mouse models of locoregional pancreatic tumours. 131I-ELP brachytherapy was effective independently of the paclitaxel formulation and dose, but external beam radiotherapy (EBRT) only achieved tumour-growth inhibition when co-administered with nanoparticle paclitaxel. Histological analyses revealed that 131I-ELP brachytherapy led to changes in the expression of intercellular collagen and junctional proteins within the tumour microenvironment. These changes, which differed from those of EBRT-treated tumours, correlated with the improved delivery and accumulation of paclitaxel nanoparticles within the tumour. Our findings support the further translational development of 131I-ELP depots for the synergistic treatment of localized pancreatic cancer.
Authors
Schaal, JL; Bhattacharyya, J; Brownstein, J; Strickland, KC; Kelly, G; Saha, S; Milligan, J; Banskota, S; Li, X; Liu, W; Kirsch, DG; Zalutsky, MR; Chilkoti, A
MLA Citation
Schaal, Jeffrey L., et al. “Brachytherapy via a depot of biopolymer-bound 131I synergizes with nanoparticle paclitaxel in therapy-resistant pancreatic tumours.” Nat Biomed Eng, vol. 6, no. 10, Oct. 2022, pp. 1148–66. Pubmed, doi:10.1038/s41551-022-00949-4.
URI
https://scholars.duke.edu/individual/pub1554201
PMID
36261625
Source
pubmed
Published In
Nature Biomedical Engineering
Volume
6
Published Date
Start Page
1148
End Page
1166
DOI
10.1038/s41551-022-00949-4
Double-stranded RNA drives SARS-CoV-2 nucleocapsid protein to undergo phase separation at specific temperatures.
Nucleocapsid protein (N-protein) is required for multiple steps in betacoronaviruses replication. SARS-CoV-2-N-protein condenses with specific viral RNAs at particular temperatures making it a powerful model for deciphering RNA sequence specificity in condensates. We identify two separate and distinct double-stranded, RNA motifs (dsRNA stickers) that promote N-protein condensation. These dsRNA stickers are separately recognized by N-protein's two RNA binding domains (RBDs). RBD1 prefers structured RNA with sequences like the transcription-regulatory sequence (TRS). RBD2 prefers long stretches of dsRNA, independent of sequence. Thus, the two N-protein RBDs interact with distinct dsRNA stickers, and these interactions impart specific droplet physical properties that could support varied viral functions. Specifically, we find that addition of dsRNA lowers the condensation temperature dependent on RBD2 interactions and tunes translational repression. In contrast RBD1 sites are sequences critical for sub-genomic (sg) RNA generation and promote gRNA compression. The density of RBD1 binding motifs in proximity to TRS-L/B sequences is associated with levels of sub-genomic RNA generation. The switch to packaging is likely mediated by RBD1 interactions which generate particles that recapitulate the packaging unit of the virion. Thus, SARS-CoV-2 can achieve biochemical complexity, performing multiple functions in the same cytoplasm, with minimal protein components based on utilizing multiple distinct RNA motifs that control N-protein interactions.
Authors
Roden, CA; Dai, Y; Giannetti, CA; Seim, I; Lee, M; Sealfon, R; McLaughlin, GA; Boerneke, MA; Iserman, C; Wey, SA; Ekena, JL; Troyanskaya, OG; Weeks, KM; You, L; Chilkoti, A; Gladfelter, AS
MLA Citation
Roden, Christine A., et al. “Double-stranded RNA drives SARS-CoV-2 nucleocapsid protein to undergo phase separation at specific temperatures.” Nucleic Acids Research, vol. 50, no. 14, Aug. 2022, pp. 8168–92. Epmc, doi:10.1093/nar/gkac596.
URI
https://scholars.duke.edu/individual/pub1530076
PMID
35871289
Source
epmc
Published In
Nucleic Acids Research
Volume
50
Published Date
Start Page
8168
End Page
8192
DOI
10.1093/nar/gkac596
Aerosol jet printing of biological inks by ultrasonic delivery.
Printing is a promising method to reduce the cost of fabricating biomedical devices. While there have been significant advancements in direct-write printing techniques, non-contact printing of biological reagents has been almost exclusively limited to inkjet printing. Motivated by this lacuna, this work investigated aerosol jet printing (AJP) of biological reagents onto a nonfouling polymer brush to fabricate in vitro diagnostic (IVD) assays. The ultrasonication ink delivery process, which had previously been reported to damage DNA molecules, caused no degradation of printed proteins, allowing printing of a streptavidin-biotin binding assay with sub-nanogram ml<sup>-1</sup> analytical sensitivity. Furthermore, a carcinoembryogenic antigen IVD was printed and found to have sensitivities in the clinically relevant range (limit of detection of approximately 0.5 ng ml<sup>-1</sup> and a dynamic range of approximately three orders of magnitude). Finally, the multi-material printing capabilities of the aerosol jet printer were demonstrated by printing silver nanowires and streptavidin as interconnected patterns in the same print job without removal of the substrate from the printer, which will facilitate the fabrication of mixed-material devices. As cost, versatility, and ink usage become more prominent factors in the development of IVDs, this work has shown that AJP should become a more widely considered technique for fabrication.
Authors
Williams, NX; Watson, N; Joh, DY; Chilkoti, A; Franklin, AD
MLA Citation
Williams, Nicholas X., et al. “Aerosol jet printing of biological inks by ultrasonic delivery.” Biofabrication, vol. 12, no. 2, Feb. 2020, p. 025004. Epmc, doi:10.1088/1758-5090/ab5cf5.
URI
https://scholars.duke.edu/individual/pub1422342
PMID
31778993
Source
epmc
Published In
Biofabrication
Volume
12
Published Date
Start Page
025004
DOI
10.1088/1758-5090/ab5cf5
2.5 Elastin-like polypeptides
Elastin-like polypeptides are a family of stimuli-responsive biopolymers that have been extensively studied for biomedical applications. Derived from tropoelastin, they mimic many of elastin’s remarkable material properties, yet can be designed with a molecular precision surpassing synthetic polymers. Their biocompatibility and stimuli-responsive phase behavior have allowed them to be used in a variety of biomedical applications ranging from self-assembling, drug-loaded nanoparticles to injectable cell scaffolds and drug depots.
Authors
Roberts, S; Costa, S; Schaal, J; Simon, JR; Dzuricky, M; Quiroz, FG; Chilkoti, A
MLA Citation
Roberts, S., et al. “2.5 Elastin-like polypeptides.” Comprehensive Biomaterials II, 2017, pp. 90–108. Scopus, doi:10.1016/B978-0-12-803581-8.09308-5.
URI
https://scholars.duke.edu/individual/pub1432549
Source
scopus
Published Date
Start Page
90
End Page
108
DOI
10.1016/B978-0-12-803581-8.09308-5

Alan L. Kaganov Distinguished Professor of Biomedical Engineering
Contact:
1427 CIEMAS, Durham, NC 27708
Box 90281, Durham, NC 27708-0281